Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BullFrog AI Holdings, Inc. ( (BFRG) ).
On March 27, 2026, BullFrog AI Holdings, Inc. entered into a one-year feasibility agreement with a top five global pharmaceutical company to apply its bfLEAP AI and machine learning platform to identify and prioritize novel drug targets for major depressive disorder. The arrangement, announced on March 30, 2026, includes milestone-based payments, an option for the customer to secure exclusive rights to a selected target candidate for three years, and standard protections around intellectual property and confidentiality, marking a significant commercial validation of BullFrog AI’s platform in a large and growing MDD market.
The deal positions BullFrog AI as a high-profile partner in applying end-to-end analytical AI to accelerate drug discovery and clinical development for complex psychiatric conditions. For the pharmaceutical partner, the collaboration offers a data-driven approach to derisking target selection in a market valued at more than $8 billion in 2025 and projected to exceed $11 billion by 2032, while potentially laying groundwork for broader use of BullFrog AI’s technology across its R&D portfolio.
More about BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc. is a technology company that leverages artificial intelligence and machine learning to advance drug discovery and development. Using its proprietary bfLEAP platform and causal AI, it analyzes complex biological data to streamline therapeutic development and reduce clinical trial failure rates, working through collaborations with leading research institutions.
Average Trading Volume: 681,920
Technical Sentiment Signal: Sell
Current Market Cap: $6.44M
For a thorough assessment of BFRG stock, go to TipRanks’ Stock Analysis page.